



**SR-T100 New Drug Clinical trials and
Current Business Status of G&E**

Kuo, Kou-Wha, Ph.D.

**Chairman, G&E Herbal Biotech Co., Ltd.
CEO, Research Center of Botanical Medicines**

2025. 08. 08

G&E Herbal Biotechnology Co., Ltd. **Company own land, 12046 m²**

(PIC/S GMP Pharmaceutical Factory · Raw Material Pharmaceutical Factory · Plant Extraction Factory · GMP Food Factory · Cosmetic Factory)



DISCLAIMER

- **The content of this briefing makes every effort to ensure the accuracy and reliability of the data provided, but does not guarantee that 100% is absolutely accurate and reliable, and therefore will not be liable for any loss or damage to whom arising from any inaccuracies or omissions. Investors are advised to analyze and analyze the relevant data on the basis of public information, and this report should not be construed as lobbying any investor to carry out any transaction, and the investor must be responsible for all transactions executed.**
- **Development of new drugs is time consuming, high investment and does not guarantee success. These may put the investments at risk. Investors should be careful to make prudent investments.**

COMPANY PROFILE

Founded: August 6, 2002

Amount of Capital: NT \$ 637,195,680

Stock on the date of OTC: March 21, 2011

Chairman: Kou-Wha Kuo, Ph.D

Development of global new ingredient of SR-T100 new drug and the current revenue sources of G&E company:

New drug development projects	Patented SR-T100	injection	Treatment of malignant ascites of cancers
		Topical Gel	Treatment of skin cancer, HPV (genital warts, common warts)
Current source of revenues	Hepanamin®	The highest bioavailability of Silymarin in the world for the treatments of traditional hepatobiliary diseases, Non-Alcoholic fatty liver, Non-Alcoholic Steatohepatitis and chronic kidney diseases	
	Eye health food	Highly effective eye food supplement (within 30 minutes)	
	Anti-wrinkle brightening skincare products	SR-100 Patented Anti-Aging Series Skin Care Products	
	Functional skin cares	uremic pruritus, varicose veins, swelling and bruising, wound healing	

Innovation Affirmation and Glory of G&E from Taiwan Government



**TFDA Science and Technology
Development award
Gold Medal**

2012 Ministry of
Economy and TFDA



**National inventions
Gold Medal**

2011 Ministry of Economy
Intelligent Property Bureau



**R&D Innovation Award
Gold Medal**

2010 Taipei Municipal
Government
Taipei Biotech Award



**Technology Innovation
Achievement Award**

2011 Ministry of Economy
Technical Department



**Health Medical
Gold Medal**

2010 Executive Yuan of
Healthcare and Farm Health
contest



**Prospect Technology
Innovation Award**

2009 Ministry of Economy
Industrial Science and Technology
Development award

Not all the diseases can be clinically treated with appropriate medications!


- **No harms to the hematopoietic and immune systems of anticancer drug**
- **Malignant ascites caused by cancer**
- **Liver cirrhosis**
- **Non-alcoholic fatty liver disease (NAFLD) and Inflammation (NASH)**
- **Eye soreness, astringency, stickiness, blurring, dry eye syndrome, floaters, photophobia, double vision, ...**
- **Chronic Kidney Disease**
- **Uremia pruritus in dialysis patients 、 Artificial vessel obstruction**
- **Severe varicose veins**


Revenue Growth Trend Chart from 2022 to July 2025



2023~2024 Cash and Stock Dividend Distribution Table

Year	Distributable surplus (Yuan)	Cash dividends (Yuan)	Cash dividend per share (Yuan)	Distribution of stock dividends(Yuan)	Dividends per stock	Total number of shares after issuance (shares)
2023	65,160,361	31,764,361	570.68560	33,396,000	60股	58,999,600
2024	91,857,026	44,657,346	756.90930	47,199,680	80股	63,719,568






According to the forecast of Deutsche Bank and Evaluate Pharma, the global NASH drug market will reach 350~40 billion US dollars in 2025.

SR-T100 New Drug Developments and Current Status

SR-T100 is a clinical trials approved by the TFDA and USFDA.

Product Name		Clinical Trials				
		Pre-clinic study	Pilot clinic trial	Phase I	Phase II	Phase III
SR-T100 Gel	Actinic keratosis (Solar keratosis)				US FDA TFDA	US FDA TFDA
	Genital warts (Condyloma)			TFDA	US FDA TFDA	US FDA TFDA
SR-T100 Injection				TFDA	US FDA TFDA	

Progress and Planning of Clinical Trials of SR-T100



Summary for Shareholder References

- 1. Since its establishment, the company has never handled a capital increase or loan to a bank except for a small capital increase in accordance with laws and regulations when the stock was listed on the OTC in 2011, and at the same time purchased land and completed the construction of PIC/S GMP pharmaceutical factory, API factory, extraction factory, food factory and skin care product factory. The food factory is a PIC/S GMP pharmaceutical factory approved by the Ministry of Health and Welfare to produce food, and the maintenance product factory is implementing GMP certification in response to the new regulations of the Ministry of Health and Welfare, and has reserved 1,700 square meters of land for the expansion of the factory.**
- 2. Since its inception, the company's financial statements have begun to turn into profits and profits have gradually increased, and the operating performance in 2024 has been better than in 2023, so the company has a philosophy, potential, decent operation and one of the few profitable new drug development companies in Taiwan (as detailed in the financial report announcement).**

- 4. Hepanamin® has the highest dissolution rate according to the pharmacopoeia, which is one of the few drugs in the world that can fully meet the specifications of the Taiwan and USA pharmacopoeia, and is helpful in treating liver, gallbladder and kidney diseases that were difficult to treat in the past.**
- 5. SR-T100 injection is the main focus for the treatment of malignant ascites, and if successfully, it will be the only drug in the world that can eliminate cancer malignant ascites.**
- 6. The phase III human clinical trial of SR-T100 topical gel for the treatments of genital warts and skin cancer will be completed after the development of the SR-T100 injection is on track.**
- 7. To maintain the revenue of SR-100 related health foods, skin care products and drugs, the International Affairs Department has been established, and efforts will be gradually made in the future to promote international authorization, joint development, and the establishment of foreign channels.**

Q&A

Investor Conference

G&E Herbal Biotechnology Co., Ltd.